With BostonGene Tumor Portrait Tests, WellDyne will increase efficiency and therapy selection for patients who are candidates for immunotherapy in melanoma, non-small cell lung cancer, gastric, bladder and kidney cancers.
BostonGene Corp., a biomedical software company, is committed to defining optimal, precision medicine-based therapies for cancer patients.
As a pharmacy benefit manager, WellDyne leverages precision medicine's targeted approach that can predict how a patient will metabolize and respond to specific drugs.
The BostonGene Molecular Functional Portrait (MF Portrait) will assist WellDyne in determining patient eligibility for immunotherapy treatment based on its comprehensive analysis of the tumor and the microenvironment.
With the implementation of this test, WellDyne will better understand and manage the total cost of care for patients.
The BostonGene Tumor Portrait Test, based on integrated genomic and transcriptomic analysis, reveals key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies.
The test significantly increases the correct identification of patients who respond to immunotherapy and helps other patients avoid unnecessary adverse events.
It combines precise data processing and proprietary algorithms to generate easy-to-understand tumor schematics, including the MF Portrait, a personalized tumor map to guide treatment decision-making that tailors individualized treatments and streamlines treatment costs.
BostonGene's mission is to power healthcare's transition to personalized medicine using AI-based molecular and immune profiling to improve the standard of care, accelerate research and improve economics.
BostonGene Tumor Portrait Tests reveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies.
Through these analyses, BostonGene Tumor Portrait Tests generate a personalized roadmap for therapeutic decision-making for each cancer patient.
For more than 25 years, WellDyne has leveraged its deep clinical expertise to achieve better patient outcomes and reduce pharmacy trend.
Knowing that medications are among the safest, easiest and lowest cost treatments to help people live their best lives, the company believes a smarter approach to the delivery of PBM services unleashes the full power of medications to reduce future healthcare costs.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review